GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>ART-123 uniquely targets both coagulation and systemic inflammatory pathways...Is that true?<

It’s true if you take out the word uniquely. If you leave uniquely in, then it’s a line-drawing game.

>Atryn's anti-inflammatory properties are not in that category?<

The MoA of ART-123/thrombomodulin is similar to that of antithrombin because the molecule is a fragment of antithrombin. However, I think it’s reasonable to expect that ART-123 will have a more difficult U.S. regulatory path than ATryn because ART-123 is not structurally close enough to plasma antithrombin for the FDA to presume that it will work the same way.